(NEOG) Neogen - Ratings and Ratios
Diagnostics, Kits, Culture, Reagents, Consumables
NEOG EPS (Earnings per Share)
NEOG Revenue
Description: NEOG Neogen August 21, 2025
Neogen Corporation is a US-based company operating in the Health Care Supplies sub-industry, with its common stock listed on NASDAQ under the ticker symbol NEOG.
The companys current market capitalization stands at approximately $1.1 billion, indicating a significant presence in the market. However, the negative Return on Equity (ROE) of -41.46% raises concerns about its profitability and ability to generate returns for shareholders.
The forward Price-to-Earnings (P/E) ratio of 16.00 suggests that investors have certain expectations for the companys future earnings growth. To meet these expectations, Neogen will need to demonstrate improved profitability and a robust growth trajectory.
Key economic drivers for Neogen Corporation likely include demand for healthcare supplies, trends in the diagnostics and food safety testing markets, and the overall performance of the healthcare industry. To gauge the companys performance, investors may monitor KPIs such as revenue growth, gross margin expansion, and operating cash flow generation.
A critical analysis of Neogens quarterly tax provision is essential to understanding its financial health and identifying potential areas for improvement. A thorough examination of the tax provision can reveal insights into the companys effective tax rate, potential tax liabilities, and the impact of tax-related factors on its bottom line.
To drive growth and improve profitability, Neogen may need to focus on strategic initiatives such as expanding its product portfolio, enhancing operational efficiency, and investing in research and development to stay competitive in the healthcare supplies market.
NEOG Stock Overview
| Market Cap in USD | 1,312m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 1989-08-23 |
NEOG Stock Ratings
| Growth Rating | -83.4% |
| Fundamental | 28.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -66.7% |
| Analyst Rating | 4.33 of 5 |
NEOG Dividends
Currently no dividends paidNEOG Growth Ratios
| Growth Correlation 3m | 77.7% |
| Growth Correlation 12m | -73.5% |
| Growth Correlation 5y | -90.6% |
| CAGR 5y | -27.88% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.34 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.75 |
| Sharpe Ratio 12m | -1.11 |
| Alpha | -92.27 |
| Beta | 1.985 |
| Volatility | 49.06% |
| Current Volume | 3956.7k |
| Average Volume 20d | 3661.7k |
| Stop Loss | 5.6 (-6.4%) |
| Signal | -0.16 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-1.04b TTM) > 0 and > 6% of Revenue (6% = 53.2m TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA 2.63pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 42.60% (prev 45.82%; Δ -3.21pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 85.0m > Net Income -1.04b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (217.0m) change vs 12m ago 0.16% (target <= -2.0% for YES) |
| Gross Margin 35.86% (prev 47.39%; Δ -11.54pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 22.51% (prev 20.26%; Δ 2.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -14.46 (EBITDA TTM -885.5m / Interest Expense TTM 69.4m) >= 6 (WARN >= 3) |
Altman Z'' -1.87
| (A) 0.11 = (Total Current Assets 524.1m - Total Current Liabilities 146.2m) / Total Assets 3.38b |
| (B) -0.15 = Retained Earnings (Balance) -500.1m / Total Assets 3.38b |
| (C) -0.25 = EBIT TTM -1.00b / Avg Total Assets 3.94b |
| (D) -0.39 = Book Value of Equity -488.8m / Total Liabilities 1.26b |
| Total Rating: -1.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.19
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -0.26% = -0.13 |
| 3. FCF Margin -0.58% = -0.22 |
| 4. Debt/Equity 0.37 = 2.43 |
| 5. Debt/Ebitda -0.74 = -2.50 |
| 6. ROIC - WACC (= -33.76)% = -12.50 |
| 7. RoE -43.83% = -2.50 |
| 8. Rev. Trend -46.44% = -3.48 |
| 9. EPS Trend 31.80% = 1.59 |
What is the price of NEOG shares?
Over the past week, the price has changed by -0.33%, over one month by +6.22%, over three months by +25.37% and over the past year by -61.72%.
Is Neogen a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NEOG is around 4.28 USD . This means that NEOG is currently overvalued and has a potential downside of -28.43%.
Is NEOG a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NEOG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.2 | 36.6% |
| Analysts Target Price | 8.2 | 36.6% |
| ValueRay Target Price | 4.8 | -19.9% |
NEOG Fundamental Data Overview November 06, 2025
P/E Forward = 16.0
P/S = 1.4799
P/B = 0.608
P/EG = 0.6575
Beta = 1.985
Revenue TTM = 886.9m USD
EBIT TTM = -1.00b USD
EBITDA TTM = -885.5m USD
Long Term Debt = 874.8m USD (from longTermDebt, last fiscal year)
Short Term Debt = 27.4m USD (from shortTermDebt, last fiscal year)
Debt = 792.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 653.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.97b USD (1.31b + Debt 792.5m - CCE 138.9m)
Interest Coverage Ratio = -14.46 (Ebit TTM -1.00b / Interest Expense TTM 69.4m)
FCF Yield = -0.26% (FCF TTM -5.17m / Enterprise Value 1.97b)
FCF Margin = -0.58% (FCF TTM -5.17m / Revenue TTM 886.9m)
Net Margin = -117.6% (Net Income TTM -1.04b / Revenue TTM 886.9m)
Gross Margin = 35.86% ((Revenue TTM 886.9m - Cost of Revenue TTM 568.9m) / Revenue TTM)
Gross Margin QoQ = 34.40% (prev 30.75%)
Tobins Q-Ratio = 0.58 (Enterprise Value 1.97b / Total Assets 3.38b)
Interest Expense / Debt = 2.07% (Interest Expense 16.4m / Debt 792.5m)
Taxrate = 17.05% (7.47m / 43.8m)
NOPAT = -833.0m (EBIT -1.00b * (1 - 17.05%)) [loss with tax shield]
Current Ratio = 3.58 (Total Current Assets 524.1m / Total Current Liabilities 146.2m)
Debt / Equity = 0.37 (Debt 792.5m / totalStockholderEquity, last quarter 2.12b)
Debt / EBITDA = -0.74 (negative EBITDA) (Net Debt 653.6m / EBITDA -885.5m)
Debt / FCF = -126.4 (out of range, set to none) (Net Debt 653.6m / FCF TTM -5.17m)
Total Stockholder Equity = 2.38b (last 4 quarters mean from totalStockholderEquity)
RoA = -30.88% (Net Income -1.04b / Total Assets 3.38b)
RoE = -43.83% (Net Income TTM -1.04b / Total Stockholder Equity 2.38b)
RoCE = -30.86% (EBIT -1.00b / Capital Employed (Equity 2.38b + L.T.Debt 874.8m))
RoIC = -24.80% (negative operating profit) (NOPAT -833.0m / Invested Capital 3.36b)
WACC = 8.96% (E(1.31b)/V(2.11b) * Re(13.33%) + D(792.5m)/V(2.11b) * Rd(2.07%) * (1-Tc(0.17)))
Discount Rate = 13.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.15%
Fair Price DCF = unknown (Cash Flow -5.17m)
EPS Correlation: 31.80 | EPS CAGR: 212.3% | SUE: 2.02 | # QB: 2
Revenue Correlation: -46.44 | Revenue CAGR: -3.40% | SUE: 1.06 | # QB: 1
Additional Sources for NEOG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle